Literature DB >> 30035844

Dystonia: diagnosis and management.

A Albanese1,2, M Di Giovanni1, S Lalli1,2.   

Abstract

Clinical practice in dystonia has greatly evolved in recent years; a synthetic review on patient management is provided here. Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures or both. A recent classification has innovated clinical practice and serves as guidance for clinical assessment: Axis I describes clinical features, whereas Axis II indicates etiology. Dystonia presents with different syndromic aggregations with varied somatic involvement and some common features. There are five recognizable physical signs of dystonia: two main signs (dystonic postures and movements) and three additional signs (gestes antagonistes or tricks, mirror dystonia and overflow dystonia). There is still no validation of diagnostic criteria for the different dystonia syndromes, and many cases with mild phenomenology remain undiagnosed. Patients with dystonia also present non-motor features that are variably combined with the movement disorder. The features of the most common inherited and acquired dystonia syndromes are reviewed here. There is clear evidence of genetic-environmental interaction in the determinism of dystonia. The diagnostic process is guided by clinical examination and based on specific laboratory examinations. Symptomatic treatments are available for dystonia: botulinum neurotoxin injections are the primary choice for most focal dystonia syndromes; deep brain stimulation is useful in some generalized and non-generalized syndromes. Additional treatment strategies are currently being assessed.
© 2018 EAN.

Entities:  

Keywords:  classification; diagnosis; dystonia; genetics; phenotypes

Mesh:

Year:  2018        PMID: 30035844     DOI: 10.1111/ene.13762

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Dystonia and leveraging oral pharmacotherapy.

Authors:  Michelle Ann C Sy; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-20       Impact factor: 3.575

3.  Secondary atlantoaxial subluxation in isolated cervical dystonia-a case report.

Authors:  Eric Chun-Pu Chu; Fa-Sain Lo; Amiya Bhaumik
Journal:  AME Case Rep       Date:  2020-04-30

4.  Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.

Authors:  Angela Jochim; Tobias Meindl; Christoph Huber; Tobias Mantel; Silke Zwirner; Florian Castrop; Bernhard Haslinger
Journal:  J Neurol       Date:  2019-10-19       Impact factor: 4.849

5.  Diverse Mechanisms Lead to Common Dysfunction of Striatal Cholinergic Interneurons in Distinct Genetic Mouse Models of Dystonia.

Authors:  Karen L Eskow Jaunarajs; Mariangela Scarduzio; Michelle E Ehrlich; Lori L McMahon; David G Standaert
Journal:  J Neurosci       Date:  2019-07-18       Impact factor: 6.167

6.  Lack of Association of the rs11655081 ARSG Gene with Blepharospasm.

Authors:  Vasileios Siokas; Dimitrios Kardaras; Athina-Maria Aloizou; Ioannis Asproudis; Konstadinos G Boboridis; Eleni Papageorgiou; Demetrios A Spandidos; Aristidis Tsatsakis; Evangelia E Tsironi; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-01-18       Impact factor: 3.444

7.  Spasmodic dysphonia as a presenting symptom of spinocerebellar ataxia type 12.

Authors:  Jessica Rossi; Francesco Cavallieri; Giada Giovannini; Carla Budriesi; Annalisa Gessani; Miryam Carecchio; Daniela Di Bella; Elisa Sarto; Jessica Mandrioli; Sara Contardi; Stefano Meletti
Journal:  Neurogenetics       Date:  2019-06-13       Impact factor: 2.660

Review 8.  The apparent paradox of phenotypic diversity and shared mechanisms across dystonia syndromes.

Authors:  Alessio Di Fonzo; Alberto Albanese; Hyder A Jinnah
Journal:  Curr Opin Neurol       Date:  2022-07-05       Impact factor: 6.283

9.  OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.

Authors:  Pinky Agarwal; Richard Barbano; Henry Moore; Marc Schwartz; Aleksej Zuzek; Marjan Sadeghi; Atul Patel
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

10.  Implementation of the Current Dystonia Classification from 2013 to 2018.

Authors:  Sanskriti Sasikumar; Alberto Albanese; Joachim K Krauss; Alfonso Fasano
Journal:  Mov Disord Clin Pract       Date:  2019-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.